Adcetris 50mg Injection (Brentuximab Vedotin) – Imported

Adcetris 50mg Injection contains Brentuximab Vedotin, a prescription-only targeted cancer therapy used in the treatment of certain CD30-positive lymphomas. It belongs to a specialised class of medicines known as antibody-drug conjugates (ADCs), which combine a targeted antibody with a cell-killing agent to deliver treatment to cancer cells expressing the CD30 protein.

Adcetris is used under the supervision of an experienced oncologist for specific types of Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and other approved CD30-positive malignancies. It may be prescribed alone or in combination with other chemotherapy medicines, depending on the patient’s diagnosis, treatment history, and clinical condition.

The product shown contains 50mg of Brentuximab Vedotin in a single-use vial. It is supplied as a powder concentrate that requires reconstitution and dilution before intravenous infusion. Adcetris is a specialised imported oncology medicine and must only be administered by trained healthcare professionals.

Product Information

• Brand Name: Adcetris
• Generic Name: Brentuximab Vedotin
• Strength: 50mg/vial
• Dosage Form: Powder for concentrate for solution for infusion
• Route of Administration: Intravenous (IV) infusion
• Manufacturer: BSP Pharmaceuticals S.p.A.
• Secondary Packing and Release: Takeda Australia
• Pack Size: 1 single-use vial
• Therapeutic Category: CD30-directed antibody-drug conjugate
• Availability: Imported specialty oncology medicine

What Is Adcetris 50mg Injection Used For?

Brentuximab Vedotin is prescribed for certain cancers in which malignant cells express the CD30 protein. Its approved uses depend on the applicable prescribing information and treatment protocol.

1. Classical Hodgkin Lymphoma (cHL)

Adcetris is used in adults with selected forms and stages of classical Hodgkin lymphoma. It may be prescribed as part of an initial combination chemotherapy regimen, as consolidation treatment following an autologous stem cell transplant in patients at increased risk of relapse, or for relapsed or refractory disease in eligible patients.

2. Systemic Anaplastic Large Cell Lymphoma (sALCL)

Adcetris is used in certain patients with systemic anaplastic large cell lymphoma, a type of peripheral T-cell lymphoma associated with CD30 expression. It may be used in previously untreated disease in combination with chemotherapy or in selected cases of relapsed or refractory disease.

3. Other CD30-Positive Lymphomas

Depending on the approved indication and clinical circumstances, Brentuximab Vedotin may also be used for selected CD30-positive peripheral T-cell lymphomas and other specified malignancies. The oncologist determines whether the medicine is appropriate based on the cancer subtype, CD30 status, and treatment history.

How Does Brentuximab Vedotin Work?

Brentuximab Vedotin is a CD30-directed antibody-drug conjugate. It consists of a monoclonal antibody that recognises the CD30 protein on certain cancer cells, linked to a potent microtubule-disrupting agent called monomethyl auristatin E (MMAE).

After binding to CD30, the medicine is taken into the target cell. The linked MMAE is then released inside the cell, where it disrupts microtubule function and interferes with cell division. This can lead to cancer-cell death.

This targeted delivery mechanism distinguishes Adcetris from conventional chemotherapy, although it can still cause serious side effects and affect healthy tissues.

Dosage and Administration

Adcetris 50mg is supplied as a single-use vial containing 50mg of Brentuximab Vedotin. The dose is not automatically one complete vial per patient.

The prescribed dose and treatment schedule depend on the specific cancer indication, body weight, treatment combination, previous therapies, organ function, and individual clinical response.

Adcetris is administered through intravenous infusion only. The powder must be reconstituted and diluted according to the official product instructions before administration.

Important administration considerations:

• It must be prepared using appropriate aseptic technique.
• It is administered by a qualified healthcare professional.
• It must not be administered as a direct injection.
• The prepared solution must be inspected before administration.
• Any unused portion in the single-use vial must be discarded according to the product instructions.
• Patients should follow the exact schedule prescribed by their oncologist.

Do not attempt to prepare or administer Adcetris at home.

Possible Side Effects

Adcetris can cause side effects, and their severity varies depending on the patient and treatment regimen.

Commonly reported adverse reactions include:

• Peripheral neuropathy, including numbness or tingling in the hands and feet
• Fatigue and weakness
• Nausea and vomiting
• Diarrhoea or constipation
• Fever
• Reduced appetite
• Hair loss
• Low white blood cell counts
• Low platelet counts
• Anaemia
• Increased liver enzyme levels

Important serious risks

Brentuximab Vedotin carries important safety warnings. These include progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection associated with JC virus; serious infections; severe infusion-related reactions; peripheral neuropathy; and blood-cell abnormalities.

Patients should promptly report new neurological symptoms, persistent fever, unusual bleeding, severe weakness, breathing difficulties, or signs of a serious infection to their treating medical team.

Precautions and Warnings

Before starting Adcetris treatment, patients should inform their oncologist about their medical history, previous cancer treatments, existing infections, and all medicines they are taking.

Peripheral neuropathy: Patients should report numbness, tingling, pain, or weakness in their hands or feet. Dose modification may be required.

Infections: Treatment can affect blood-cell counts and increase the risk of infection. Regular blood tests and clinical monitoring are important.

Liver function: Patients with liver impairment may require special assessment and dose adjustment. The medicine may not be appropriate for some patients with significant hepatic impairment.

Neurological symptoms: New confusion, changes in vision, difficulty speaking, weakness, or changes in coordination require urgent medical evaluation because of the risk of PML.

Infusion reactions: Patients should be monitored during administration for allergic or infusion-related reactions.

Pregnancy and breastfeeding: Brentuximab Vedotin may harm an unborn baby. Pregnancy prevention and breastfeeding advice should be discussed with the treating specialist.

Contraindications and Drug Interactions

Adcetris must not be administered with bleomycin because the combination can cause serious pulmonary toxicity.

Certain medicines can also affect Brentuximab Vedotin exposure or increase the risk of adverse effects. Patients should disclose all prescription medicines, supplements, and previous or ongoing cancer treatments to their oncologist.

Storage Instructions

• Follow the storage conditions printed on the original packaging and official product information.
• Protect the unopened vial from inappropriate storage conditions.
• Reconstituted and diluted solutions must be handled within the specified stability period.
• Do not use damaged, expired, or improperly stored products.
• Keep the medicine out of reach of children.

Adcetris 50mg Injection Price in Pakistan

The Adcetris 50mg Injection price in Pakistan may vary according to import availability, supplier pricing, batch details, and market conditions.

For the latest price, stock status, and ordering information, contact MedicineWalyDost.com. Our team can assist with enquiries regarding imported specialty oncology medicines.

Frequently Asked Questions (FAQs)

1. What is Adcetris 50mg Injection used for?

Adcetris contains Brentuximab Vedotin and is used for selected CD30-positive cancers, including classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

2. What is the generic name of Adcetris?

The generic name is Brentuximab Vedotin.

3. What is the strength of Adcetris?

Each single-use vial contains 50mg of Brentuximab Vedotin.

4. Who manufactures Adcetris shown in the supplied packaging?

The packaging identifies BSP Pharmaceuticals S.p.A. as the manufacturer, with Takeda Australia responsible for secondary packing and release.

5. How many vials are included in one pack?

The supplied product packaging indicates one single-use vial.

6. Is Adcetris administered intravenously?

Yes. Adcetris is administered through intravenous infusion after professional reconstitution and dilution.

7. Is Adcetris a chemotherapy medicine?

It is a targeted antibody-drug conjugate. It combines a CD30-directed antibody with a cell-killing agent and is used in oncology treatment protocols.

8. Does Adcetris cause hair loss?

Hair loss can occur, particularly when Adcetris is used in combination with chemotherapy. The likelihood depends on the treatment regimen.

9. Can Adcetris be administered at home?

No. It requires professional preparation and intravenous administration in an appropriate healthcare setting.

10. Is Adcetris 50mg Injection available in Pakistan?

For current availability and pricing, contact MedicineWalyDost.com.

Order Adcetris 50mg Injection from MedicineWalyDost.com

Looking for Adcetris 50mg Injection (Brentuximab Vedotin) in Pakistan? MedicineWalyDost.com assists customers with availability enquiries and sourcing information for imported and specialty oncology medicines.

Contact our support team to confirm current stock, product details, and delivery arrangements.

MedicineWalyDost.com – Imported & Speciality Medicines in Pakistan.

WhatsApp Support: +92 315 7733383

Medical Disclaimer: This product description is for educational and product-information purposes only. Adcetris is a prescription-only oncology medicine. Treatment selection, preparation, dosage, and administration must be managed by a qualified oncologist and trained healthcare professionals.